Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immuneering (IMRX)
NASDAQ:IMRX
Holding IMRX?
Track your performance easily
IMRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.00 - $7.68
Previous CloseN/A
Volume3.55M
Average Volume (3M)3.70M
Market Cap
$60.86M
Enterprise Value$27.89M
Total Cash (Recent Filing)$13.78M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Mar 05, 2025EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding31,050,447
10 Day Avg. Volume9,335,320
30 Day Avg. Volume3,704,277
Standard Deviation0.42
R-Squared0.00162
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3072.70
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue1.45K
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.48
Forecast
1Y Price Target
$11.50Price Target Upside486.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Immuneering News
PremiumMarket News
3 Penny Stocks to Watch Now, 1/9/25
PremiumCompany Announcements
Immuneering Corp. Reports Q3 Loss, Highlights ProgressBulls Say, Bears Say
Bulls Say
Efficacy And SafetyIMRX announced positive P2 efficacy and safety/tolerability data for lead asset IMM-1-104, a novel MEK inhibitor for cancer.
Financial PerformanceImmuneering raised net proceeds of $13.7M through its ATM following its update.
Potential Development And PartnershipsPlans to advance '104 into a P3 trial indicate confidence in the drug's potential.
Bears Say
Comparative AnalysisIt is unclear how the mFOLFORINOX combo fares in comparison to mFOLFORINOX monotherapy until more patient data is available.
Stock PerformanceThe stock has surprisingly declined since the announcement despite positive data.
Therapy EfficacyThe efficacy of IMM-1-104 monotherapy in 2L PDAC suggests that this therapy has limited impact in later line patients as a monotherapy.
---
Ownership Overview
30.64% Insiders
6.10% Mutual Funds
1.62% Other Institutional Investors
58.03% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMRX FAQ
What was Immuneering’s price range in the past 12 months?
Immuneering lowest stock price was $1.00 and its highest was $7.68 in the past 12 months.
What is Immuneering’s market cap?
Immuneering’s market cap is $60.86M.
When is Immuneering’s upcoming earnings report date?
Immuneering’s upcoming earnings report date is Mar 05, 2025 which is in 46 days.
How were Immuneering’s earnings last quarter?
Immuneering released its earnings results on Nov 13, 2024. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.552 by $0.062.
Is Immuneering overvalued?
According to Wall Street analysts Immuneering’s price is currently Undervalued.
Does Immuneering pay dividends?
Immuneering does not currently pay dividends.
What is Immuneering’s EPS estimate?
Immuneering’s EPS estimate is -0.43.
How many shares outstanding does Immuneering have?
Immuneering has 31,050,447 shares outstanding.
What happened to Immuneering’s price movement after its last earnings report?
Immuneering reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.552. Following the earnings report the stock price went up 13.45%.
Which hedge fund is a major shareholder of Immuneering?
Among the largest hedge funds holding Immuneering’s share is Perceptive Advisors LLC. It holds Immuneering’s shares valued at 0.
---
Immuneering Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.50 (486.73% Upside)
$11.50 (486.73% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.7%
Last 30 Days ▲ 22.5%
Last 30 Days ▲ 22.5%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-65.97%
12-Months-Change
Fundamentals
Return on Equity
-71.81%
Trailing 12-Months
Asset Growth
-39.80%
Trailing 12-Months
Company Description
Immuneering
Immuneering Corpbiopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.
---
IMRX Stock 12 Month Forecast
Average Price Target
$11.50
▲(486.73% Upside)
Technical Analysis
AlloVir
―
BioAtla
―
TScan Therapeutics
―
Sana Biotechnology
―
IDEAYA Biosciences
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering IMRX
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
-10.93%
reiterated a buy rating 4 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of -10.93% per trade.
---